Cognizant to develop clinical trial platform for TransCelerate

IT firm Cognizant today said it will develop a subscription-based platform for TransCelerate BioPharma to help pharma companies collaborate for clinical trials and accelerate development of new medicines.

TransCelerate is a non-profit organisation representing 19 major pharma companies.

The 'Shared Investigator Platform' will enable the pharma industry to bring standardisation and consistency to clinical trials, Cognizant said in a statement.

Pharm firms often deploy investigator platforms individually resulting in clinical sites using multiple environments, introducing complexity and risk.

By bringing together clinical sites and sponsors spread across the world on a common platform, they can run clinical trials more efficiently and accelerate the development of new medicines, it said.

The new platform will enhance organisational productivity by providing investigators and site staff with a central, single access point to clinical trial information, enhancing accuracy and reducing study start-up time.

It will also help pharma firms improve quality, regulatory compliance, process visibility and capacity, while reducing investigator efforts related to training, document exchange and support.

In the future, the platform may provide regulators with an efficient electronic audit process and better insight into clinical trials.

"This collaboration is an important part of TransCelerate's strategy to improve clinical trial processes in order to bring innovative new medicines to patients faster," said Jackie Kent, Eli Lilly & Co Clinical Development Information and Optimisation Senior Director and TransCelerate Shared Investigator Platform Leader.